Larry Norton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8953280/publications.pdf

Version: 2024-02-01

291	58,159	2427	1009
papers	citations	97 h-index	236 g-index

323	323	323	46255
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 2001, 344, 783-792.	27.0	10,216
2	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, The, 2005, 366, 2087-2106.	13.7	4,596
3	American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5287-5312.	1.6	1,998
4	A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. New England Journal of Medicine, 2003, 349, 1793-1802.	27.0	1,723
5	The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1999, 281, 2189.	7.4	1,661
6	Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology, 2003, 21, 1431-1439.	1.6	1,464
7	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	27.0	1,363
8	Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. Journal of Clinical Oncology, 2003, 21, 976-983.	1.6	1,202
9	Tumor Self-Seeding by Circulating Cancer Cells. Cell, 2009, 139, 1315-1326.	28.9	1,182
10	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute, 2005, 97, 1262-1271.	6.3	1,048
11	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal of Medicine, 2004, 351, 971-977.	27.0	958
12	A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis. Cell, 2012, 150, 165-178.	28.9	913
13	Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis. Journal of Cell Biology, 2000, 148, 779-790.	5.2	820
14	Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 1658.	7.4	645
15	Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung. Cancer Cell, 2011, 20, 300-314.	16.8	639
16	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
17	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment, 2001, 65, 125-134.	2.5	629
18	Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell, 2009, 16, 67-78.	16.8	609

#	Article	IF	Citations
19	Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. New England Journal of Medicine, 1994, 330, 1253-1259.	27.0	606
20	erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer. Journal of the National Cancer Institute, 1998, 90, 1346-1360.	6.3	572
21	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal of Clinical Oncology, 2008, 26, 1642-1649.	1.6	548
22	Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 1998, 90, 1205-1211.	6.3	537
23	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. Journal of Clinical Oncology, 2001, 19, 2587-2595.	1.6	531
24	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine, 2007, 357, 1496-1506.	27.0	531
25	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	1.6	522
26	Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New England Journal of Medicine, 2009, 360, 2055-2065.	27.0	504
27	Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9066-E9075.	7.1	502
28	Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes and Development, 2016, 30, 34-51.	5.9	488
29	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	7.0	396
30	The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis. Neoplasia, 2013, 15, 848-IN45.	5.3	396
31	Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology, 2002, 20, 1260-1268.	1.6	395
32	Representational Oligonucleotide Microarray Analysis: A High-Resolution Method to Detect Genome Copy Number Variation. Genome Research, 2003, 13, 2291-2305.	5.5	376
33	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics, 1996, 14, 188-190.	21.4	375
34	Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies. Journal of the National Cancer Institute, 1993, 85, 1327-1333.	6.3	372
35	Adjuvant Chemotherapy in Older and Younger Women With Lymph Nodeâ€“Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 1073.	7.4	371
36	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367

#	Article	IF	Citations
37	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2â€“Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2007, 25, 5410-5417.	1.6	333
38	Is cancer a disease of self-seeding?. Nature Medicine, 2006, 12, 875-878.	30.7	329
39	Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Research, 2006, 16, 1465-1479.	5.5	291
40	Predicting the course of Gompertzian growth. Nature, 1976, 264, 542-545.	27.8	286
41	Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer. Journal of Biological Chemistry, 2002, 277, 18649-18657.	3.4	286
42	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128.	21.4	282
43	Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. Journal of Clinical Oncology, 2007, 25, 3699-3704.	1.6	282
44	Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer, 2003, 98, 679-689.	4.1	274
45	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4340-4345.	7.1	274
46	Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2. Journal of Biological Chemistry, 2000, 275, 14838-14845.	3.4	267
47	Clinical implications of cancer self-seeding. Nature Reviews Clinical Oncology, 2011, 8, 369-377.	27.6	266
48	Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121.	7.0	263
49	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research, 2003, 6, R8-R17.	5.0	262
50	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€˜298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	13.7	260
51	Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal of Clinical Oncology, 2004, 22, 2061-2068.	1.6	257
52	Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Antiâ€“CTLA-4 Therapy. Cancer Research, 2012, 72, 430-439.	0.9	248
53	Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 2011, 3, 75ra25.	12.4	242
54	Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer, 2001, 91, 443-454.	4.1	206

#	Article	IF	Citations
55	TGF-Î²-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition. Cell Reports, 2013, 5, 1228-1242.	6.4	205
56	Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	7.0	194
57	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes and Development, 2011, 25, 226-231.	5.9	193
58	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Research and Treatment, 2001, 66, 239-248.	2.5	189
59	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
60	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. Journal of the National Cancer Institute, 2003, 95, 1548-1551.	6.3	183
61	The Nortonâ€“Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nature Clinical Practice Oncology, 2006, 3, 406-407.	4.3	182
62	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nature Communications, 2017, 8, 857.	12.8	182
63	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. Journal of Clinical Oncology, 2008, 26, 1948-1955.	1.6	176
64	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clinical Cancer Research, 2012, 18, 6784-6791.	7.0	176
65	SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers. Clinical Cancer Research, 2008, 14, 240-248.	7.0	175
66	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical Cancer Research, 2016, 22, 5729-5737.	7.0	175
67	HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptorâ€“Positive, Node-Positive Breast Cancer. Journal of Clinical Oncology, 2000, 18, 3471-3479.	1.6	168
68	Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations. Journal of the National Cancer Institute, 1999, 91, 2112-2117.	6.3	167
69	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 2005, 104, 1575-1579.	4.1	167
70	American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. Journal of Clinical Oncology, 2017, 35, 2203-2208.	1.6	167
71	Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic Therapy. Oncologist, 2005, 10, 370-381.	3.7	154
72	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€ˆ864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	10.7	147

#	Article	IF	Citations
73	Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary. American Journal of Surgical Pathology, 2005, 29, 1482-1489.	3.7	145
74	Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up. Journal of Clinical Oncology, 2008, 26, 1803-1809.	1.6	140
75	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	3.4	138
76	Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology, 2015, 237, 179-189.	4.5	133
77	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2. Cancer, 2005, 103, 44-51.	4.1	132
78	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clinical Cancer Research, 2011, 17, 3490-3499.	7.0	131
79	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clinical Cancer Research, 2017, 23, 3859-3870.	7.0	129
80	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology, 2007, 25, 2006-2011.	1.6	126
81	Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nature Communications, 2018, 9, 4141.	12.8	126
82	Factors influencing treatment patterns of breast cancer patients age 75 and older. Critical Reviews in Oncology/Hematology, 2003, 46, 121-126.	4.4	119
83	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
84	Growth Curve of an Experimental Solid Tumor Following Radiotherapy. Journal of the National Cancer Institute, 1977, 58, 1735-1741.	6.3	118
85	Intracystic Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1-14.	3.7	118
86	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clinical Breast Cancer, 2011, 11, 306-311.	2.4	118
87	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biology, 2014, 15, 484.	8.8	117
88	Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy. Oncologist, 2001, 6, 30-35.	3.7	113
89	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nature Medicine, 2017, 23, 376-385.	30.7	111
90	Current management of lesions associated with an increased risk of breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 227-238.	27.6	110

#	Article	IF	Citations
91	Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344. Journal of Clinical Oncology, 2005, 23, 30-40.	1.6	109
92	A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 7878-7883.	7.0	109
93	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biology, 2015, 16, 107.	8.8	109
94	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	12.8	105
95	Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 4287-4297.	1.6	103
96	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners. , 2000, 9, 44-56.		102
97	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
98	The Effects of Soy Supplementation on Gene Expression in Breast Cancer: A Randomized Placebo-Controlled Study. Journal of the National Cancer Institute, 2014, 106, dju189-dju189.	6.3	100
99	Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. Journal of Clinical Oncology, 2005, 23, 2191-2200.	1.6	98
100	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
101	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology, 2016, 29, 476-488.	5.5	95
102	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 2018, 9, 3533.	12.8	92
103	Genetic Heterogeneity in Therapy-NaÃ¯ve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research, 2017, 23, 4402-4415.	7.0	91
104	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	6.3	90
105	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment, 2006, 99, 295-300.	2.5	89
106	Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. International Journal of Clinical and Laboratory Research, 1994, 24, 6-14.	1.0	86
107	A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. Clinical Breast Cancer, 2006, 7, 270-277.	2.4	86
108	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patientâ€™s perspective. Breast Cancer Research and Treatment, 2006, 98, 343-348.	2.5	85

#	Article	IF	Citations
109	Focus on breast cancer. Cancer Cell, 2002, 1, 319-322.	16.8	84
110	Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21. Clinical Cancer Research, 2007, 13, 2977-2985.	7.0	83
111	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. Annals of Surgical Oncology, 2007, 14, 2510-2518.	1.5	82
112	Role of Anthracyclines in the Treatment of Early Breast Cancer. Journal of Clinical Oncology, 2009, 27, 4798-4808.	1.6	82
113	Spreaders and Sponges Define Metastasis in Lung Cancer: A Markov Chain Monte Carlo Mathematical Model. Cancer Research, 2013, 73, 2760-2769.	0.9	82
114	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Molecular Oncology, 2015, 9, 128-139.	4.6	82
115	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. Journal of Clinical Oncology, 2016, 34, 1030-1033.	1.6	82
116	Association of Angiogenesis in Lymph Node Metastases With Outcome of Breast Cancer. Journal of the National Cancer Institute, 2000, 92, 486-492.	6.3	81
117	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
118	Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute, 2005, 97, 1382-1384.	6.3	80
119	Living with Metastatic Breast Cancer: A Qualitative Analysis of Physical, Psychological, and Social Sequelae. Breast Journal, 2013, 19, 285-292.	1.0	80
120	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Modern Pathology, 2015, 28, 340-351.	5.5	80
121	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	5.2	80
122	Sleep problems in breast cancer survivors 1â€“10 years posttreatment. Palliative and Supportive Care, 2018, 16, 325-334.	1.0	80
123	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer, 2011, 117, 5461-5468.	4.1	77
124	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 2014, 9, e114900.	2.5	77
125	Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 2319-2326.	1.6	76
126	Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology, 2012, 30, 4071-4076.	1.6	76

#	Article	IF	Citations
127	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	1.6	75
128	MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYBâ€“NFIB fusion gene. Journal of Pathology, 2018, 244, 143-150.	4.5	74
129	Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients. Clinical Cancer Research, 2006, 12, 6100-6105.	7.0	72
130	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	1.6	70
131	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	6.3	68
132	Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Medical and Pediatric Oncology, 1983, 11, 76-78.	1.0	63
133	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. Npj Breast Cancer, 2017, 3, 48.	5.2	63
134	High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 2002, 20, 743-750.	1.6	61
135	Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. Clinical Cancer Research, 2004, 10, 4062-4067.	7.0	61
136	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1797-1802.	1.6	60
137	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology, 2016, 34, 2359-2365.	1.6	60
138	Randomised trial of expressive writing for distressed metastatic breast cancer patients. Psychology and Health, 2012, 27, 88-100.	2.2	59
139	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1216-1222.	1.6	56
140	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology, 2019, 37, 2338-2348.	1.6	56
141	Natural History of More Than 20 Years of Node-Positive Primary Breast Carcinoma Treated With Cyclophosphamide, Methotrexate, and Fluorouracilâ€“Based Adjuvant Chemotherapy: A Study by the Cancer and Leukemia Group B. Journal of Clinical Oncology, 2003, 21, 1825-1835.	1.6	55
142	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling, 2016, 9, ra33.	3.6	54
143	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	4.5	53
144	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events. Cancer, 2004, 101, 926-933.	4.1	52

#	Article	IF	Citations
145	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	4.5	52
146	Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial. Cancer, 1993, 71, 2515-2521.	4.1	51
147	Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast Cancer. Oncologist, 2006, 11, 1070-1071.	3.7	50
148	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	5.5	48
149	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment, 2005, 92, 151-156.	2.5	47
150	Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. JAMA Dermatology, 2019, 155, 724.	4.1	46
151	Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 628-633.	1.6	43
152	Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741. Journal of Clinical Oncology, 1999, 17, 64-64.	1.6	42
153	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer, 2004, 101, 2509-2515.	4.1	42
154	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	2.5	42
155	The MORE Trial: Multiple Outcomes for Raloxifene Evaluation. Annals of the New York Academy of Sciences, 2001, 949, 134-142.	3.8	41
156	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	9.4	41
157	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research, 2019, 25, 3784-3792.	7.0	41
158	Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Journal of Surgical Oncology, 1992, 8, 316-341.	1.4	40
159	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neuâ€“Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. Journal of Clinical Oncology, 2010, 28, 2982-2988.	1.6	40
160	Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?. Journal of Clinical Oncology, 2012, 30, 2179-2182.	1.6	40
161	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell, 2019, 36, 559-573.e7.	16.8	40
162	Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study. Journal of the National Cancer Institute, 1993, 85, 1319-1326.	6.3	39

#	Article	IF	Citations
163	Homologous recombination DNA repair defects in PALB2-associated breast cancers. Npj Breast Cancer, 2019, 5, 23.	5.2	39
164	Self-Seeding in Cancer. Recent Results in Cancer Research, 2012, 195, 13-23.	1.8	39
165	Cancer Stem Cells, Self-Seeding, and Decremented Exponential Growth: Theoretical and Clinical Implications. Breast Disease, 2008, 29, 27-36.	0.8	38
166	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	5.2	38
167	Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. Cancer Investigation, 2005, 23, 483-487.	1.3	37
168	Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Research, 2005, 7, 64-9.	5.0	37
169	Slug Promotes Survival during Metastasis through Suppression of Puma-Mediated Apoptosis. Cancer Research, 2014, 74, 3695-3706.	0.9	37
170	Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. Npj Breast Cancer, 2015, 1, 15018.	5.2	37
171	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 387-394.	2.4	37
172	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Research and Treatment, 2012, 135, 93-102.	2.5	34
173	Breast Cancer Tumor Size, Nodal Status, and Prognosis: Biology Trumps Anatomy. Journal of Clinical Oncology, 2011, 29, 2610-2612.	1.6	33
174	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal of Clinical Oncology, 2020, 38, 4120-4129.	1.6	32
175	Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer. Clinical Cancer Research, 2004, 10, 5754-5761.	7.0	31
176	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics, 2008, 9, 14.	2.7	31
177	Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840â€"Cancer and Leukemia Group B. Journal of Clinical Oncology, 2008, 26, 2659-2665.	1.6	31
178	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 69-76.	2.5	31
179	Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical Modeling. Breast Disease, 2010, 31, 7-18.	0.8	30
180	p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research, 2011, 17, 5170-5178.	7.0	30

#	Article	IF	Citations
181	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	5.2	30
182	Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3665-3673.	1.6	28
183	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	7.0	28
184	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. Npj Breast Cancer, 2016, 2, 16035.	5.2	28
185	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Research and Treatment, 2017, 165, 65-76.	2.5	28
186	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer, 2013, 13, 239-246.e1.	2.4	27
187	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist, 2017, 22, 139-143.	3.7	27
188	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment, 2006, 100, 301-308.	2.5	26
189	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. Journal of Clinical Oncology, 2009, 27, 6117-6123.	1.6	26
190	TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. Npj Breast Cancer, 2016, 2, 16009.	5.2	26
191	Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer. Drugs and Aging, 2005, 22, 785-791.	2.7	25
192	Disabling of the erbB Pathway Followed by IFN-Î³ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. Cell Reports, 2015, 12, 2049-2059.	6.4	25
193	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. Modern Pathology, 2022, 35, 193-201.	5.5	25
194	Fractional SIR epidemiological models. Scientific Reports, 2020, 10, 20882.	3.3	24
195	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2020, 108, 227-241.	0.8	24
196	Redox signaling by glutathione peroxidase 2 links vascular modulation to metabolic plasticity of breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	24
197	Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869. Journal of Clinical Oncology, 2002, 20, 732-742.	1.6	23
198	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	5.5	23

#	Article	IF	Citations
199	Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine. Clinical Cancer Research, 2007, 13, 6195-6203.	7.0	22
200	Keeping faith with trial volunteers. Nature, 2007, 446, 137-138.	27.8	22
201	The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2468-2475.	2.5	22
202	Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Research and Treatment, 2016, 157, 395-400.	2.5	22
203	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383.	6.2	21
204	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 131, 111-116.	2.5	21
205	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
206	Association between Bone Mineral Density and Incidence of Breast Cancer. PLoS ONE, 2013, 8, e70980.	2.5	21
207	Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140. Journal of Clinical Oncology, 2003, 21, 1819-1824.	1.6	20
208	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum, 2019, 3, pkz027.	2.9	20
209	Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Research, 2001, 3, 361-4.	5.0	19
210	Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Localâ€“Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1305-1313.	0.8	19
211	Accuracy of Magnetic Resonance Imagingâ€“Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy. JAMA Network Open, 2021, 4, e2034045.	5.9	19
212	Longâ€term cardiac safety and outcomes of doseâ€dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer, 2013, 119, 3943-3951.	4.1	18
213	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clinical Cancer Research, 2020, 26, 5178-5187.	7.0	18
214	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genetic Epidemiology, 2006, 30, 48-61.	1.3	17
215	Changing indications for surgery in patients with stage IV breast cancer. Cancer, 2008, 112, 1445-1454.	4.1	17
216	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â˜' trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	5.2	17

#	Article	IF	Citations
217	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer, 2011, 117, 4125-4131.	4.1	16
218	Cancer Log-Kill Revisited. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 3-7.	3.8	16
219	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical followâ€up. Cancer, 2017, 123, 131-137.	4.1	16
220	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	5.2	16
221	Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer, 1993, 71, 1254-1257.	4.1	15
222	Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Medical Oncology, 2011, 28, 39-47.	2.5	15
223	A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clinical Breast Cancer, 2017, 17, e37-e41.	2.4	15
224	Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews, 2008, 34, 223-230.	7.7	14
225	The 21-Gene Recurrence Score in Male Breast Cancer. Annals of Surgical Oncology, 2018, 25, 1530-1535.	1.5	14
226	Multisystem Toxicity in Cancer: Lessons from NASAâ€™s Countermeasures Program. Cell, 2019, 179, 1003-1009.	28.9	14
227	The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. Lancet Oncology, The, 2021, 22, 1301-1311.	10.7	14
228	Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Drugs and Aging, 2005, 22, 709-715.	2.7	13
229	A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Research and Treatment, 2009, 115, 609-612.	2.5	13
230	Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Research and Treatment, 2009, 113, 479-490.	2.5	13
231	An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer Research, 2018, 78, 103-114.	0.9	13
232	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. Npj Genomic Medicine, 2021, 6, 99.	3.8	13
233	High-Dose Chemotherapy for Breast Cancer: â€œHow Do You Know?â€• Journal of Clinical Oncology, 2001, 19, 2769-2770.	1.6	12
234	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. Clinical Breast Cancer, 2008, 8, 418-424.	2.4	12

#	Article	IF	Citations
235	Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041). Investigational New Drugs, 2004, 22, 83-89.	2.6	11
236	Radiation Pneumonitis in Breast Cancer Patients Treated with Taxanes: Does Sequential Radiation Therapy Lower the Risk?. Breast Journal, 2005, 11, 317-320.	1.0	11
237	Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer. Clinical Cancer Research, 2007, 13, 223-227.	7.0	11
238	Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. Journal of Clinical Oncology, 2008, 26, 2364-2372.	1.6	11
239	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer, 2016, 16, 276-283.	2.4	11
240	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. Molecular Oncology, 2017, 11, 913-926.	4.6	11
241	Advances in managing breast cancer: a clinical update. F1000prime Reports, 2014, 6, 66.	5.9	11
242	The treatment of combination chemotherapy-resistant Hodgkin disease with single-agent vinblastine. American Journal of Hematology, 1978, 4, 47-55.	4.1	10
243	Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 241-249.	2.7	10
244	p21CIP1 Promotes Mammary Cancerâ€“Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling. Molecular Cancer Research, 2019, 17, 1571-1581.	3.4	10
245	Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. Journal of the National Cancer Institute, 2020, 112, 107-110.	6.3	10
246	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number â‰¥4.0 and <6.0. Archives of Pathology and Laboratory Medicine, 2020, 144, 597-601.	2.5	10
247	An Intensive Sequenced Adjuvant Chemotherapy Regimen for Breast Cancer. Cancer Investigation, 1993, 11, 6-9.	1.3	9
248	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. Cancer Investigation, 1998, 16, 67-71.	1.3	9
249	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7) Tj ETQq1 1 0.784314 rgBT /Overl	5.2	9
250	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. BMC Cancer, 2018, 18, 42.	2.6	9
251	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. Cancer Research, 2019, 79, 4315-4323.	0.9	9
252	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. Annals of Surgical Oncology, 2019, 26, 329-335.	1.5	9

#	Article	IF	Citations
253	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9
254	Effect of prior radiotherapy on tolerance and response to chemotherapy in non-hodgkin's lymphoma. American Journal of Hematology, 1977, 2, 113-122.	4.1	8
255	Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology, 2010, 6, 951-965.	2.4	8
256	Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients. , 2015, 3, .		8
257	Anti-tumor effects of an ID antagonist with no observed acquired resistance. Npj Breast Cancer, 2021, 7, 58.	5.2	8
258	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners. Psycho-Oncology, 2000, 9, 44-56.	2.3	8
259	Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer. Clinical Breast Cancer, 2010, 10, 440-444.	2.4	7
260	Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis. Npj Breast Cancer, 2015, 1, 15010.	5.2	7
261	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. JAMA Network Open, 2019, 2, e1916211.	5.9	7
262	Wholeâ€exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. Histopathology, 2020, 77, 321-326.	2.9	7
263	An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Cancer Chemotherapy and Pharmacology, 2000, 46, S23-S26.	2.3	6
264	Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program. Npj Breast Cancer, 2022, 8, 14.	5.2	6
265	Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study. Npj Breast Cancer, 2022, 8, 21.	5.2	6
266	Clinical cardiotoxicity of esorubicin (4?-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases. Investigational New Drugs, 1990, 8, 221-6.	2.6	5
267	Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?. Journal of Clinical Oncology, 2012, 30, 3148-3149.	1.6	5
268	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist, 2019, 24, e646-e652.	3.7	5
269	Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy. Oncologist, 2001, 6, 30-35.	3.7	5
270	Breast Cancer Advocates in Clinical Research: A Trialist's Perspective. Breast Disease, 1998, 10, 51-59.	0.8	3

#	Article	IF	Citations
271	Stochastic Nortonâ€“Simonâ€“MassaguÃ© Tumor Growth Modeling: Controlled and Mixed-Effect Uncontrolled Analysis. IEEE Transactions on Control Systems Technology, 2021, 29, 704-717.	5.2	3
272	Adjuvant systemic therapy for early breast cancer. Journal of Surgical Oncology, 1991, 7, 283-290.	1.4	2
273	Dose-Intensity, Dose-Escalation, and Dose-Density in the Adjuvant Chemotherapy of Primary, Operable Breast Cancer. Breast Disease, 2001, 14, 81-89.	0.8	2
274	Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option. Journal of Clinical Oncology, 2008, 26, 3655-3656.	1.6	2
275	Implications of Growth Kinetic Concepts for Cancer Chemoprevention. Cancer Investigation, 1988, 6, 625-628.	1.3	1
276	Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer.. Annals of the New York Academy of Sciences, 1993, 698, 398-402.	3.8	1
277	The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results. European Journal of Cancer, Supplement, 2008, 6, 10-16.	2.2	1
278	Cell-to-cell communication in cancer: workshop report. Npj Breast Cancer, 2015, 1, 15022.	5.2	1
279	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	2.4	1
280	Reply to â€œMulticentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomasâ€• Annals of Surgical Oncology, 2019, 26, 310-311.	1.5	1
281	Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling. Journal of Clinical Oncology, 2021, 39, 253-254.	1.6	1
282	Role of Modeling in Pharmacotherapeutics. , 2006, , 3-27.		1
283	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. Blood, 2020, 136, 37-38.	1.4	1
284	Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients. Blood, 2020, 136, 30-31.	1.4	1
285	Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer. Current Oncology Reports, 2005, 7, 9-11.	4.0	0
286	Reply to S. Mahesh. Journal of Clinical Oncology, 2012, 30, 4446-4446.	1.6	0
287	Interventional immunotherapy in breast cancer. Breast Cancer Management, 2012, 1, 257-260.	0.2	0
288	Epoetin Alfa: To Give or Not to Give. Journal of the National Cancer Institute, 2013, 105, 1001-1003.	6.3	0

#	Article	IF	Citations
289	Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi). , 2014, 2, .		0
290	Dealing with the tyranny of certainty in the (medical) digital age. Psycho-Oncology, 2017, 26, 147-148.	2.3	0
291	Controlled and Uncontrolled Stochastic Norton-Simon-MassaguÃ© Tumor Growth Models. , 2019, , .		0